Management’s crowded Agenda includes meetings with Governmental Officials and intensive Factory Team Training

ANN ARBOR, Mich., – June 8, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, sends senior members of its US management and research team to Vietnam to support multiple aspects of operations focused on production expansion and development of end markets.

This trip marks the return to normal travel and the participating management team members have a packed agenda for this trip, following the lifting of travel restrictions.

Jon Rice, the Company’s Chief Operations Officer, will be traveling throughout Vietnam to support Kraig Labs’ production expansion and commercialization on several fronts. Rice will be meeting with government officials in multiple provinces to discuss additional lands for production and secure support for the further expansion of the Company’s spider silk technologies. He will hold a series of meetings with a contract silk manufacturer with the goal of securing an agreement for 3^rd party silk production. In previous discussions, this manufacturer already outlined a production scale-up plan to produce as much as 200 metric tons of silk per year. Another key goal for this trip will be meetings with Kraig Labs’ joint venture partners, PL Kings, and finalizing plans for the initial product launch under the Spydasilk brand. Rice plans to review textile mills under consideration for the production of the first recombinant spider silk fabric under the Spydasilk brand.

“This is a timely and much-needed trip that will allow us to make the best onsite decisions for Prodigy’s existing operations and the numerous potential expansion opportunities ahead. We’re also excited to bring our US and Vietnam teams together to meet the Company’s evolving needs and address, in person, a diverse list of items that will set the direction of Kraig Labs’ next growth phase,” stated Rice.

The Company is sending its senior scientist, Dr. Miller, to transfer additional process control technologies to the newly formed lab team at Prodigy Textiles, the Company’s wholly-owned Vietnamese subsidiary. Dr. Miller will provide hands-on training for the implementation of several key production initiatives, including the installation of additional laboratory and production equipment, and transferring additional R&D technology. Dr. Miller will devote the majority of his time and efforts to working with new genetic screening protocols and auditing current production processes.

“Dr. Miller’s focus will be on aligning the Prodigy laboratory team members’ efforts with his vision for the laboratory and its role in supporting production growth. This will ensure that the lab team members are optimally trained and positioned to support the production team and cement Prodigy as the top silkworm breeding facility in Vietnam,” concluded Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 27, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has kicked off the first production run of the second quarter for its recombinant spider silk.

In support of the growing production capacity at the Company’s subsidiary, Prodigy Textiles, the laboratory team has dramatically increased the testing throughput. This quality testing is the bedrock upon which the Company has been growing its spider silk production operations. Once the team completes this testing cycle, it will have increased its throughput by nearly ten times that of Q1 2022.

This milestone marks a new baseline for production capacity and sets the Company on a trajectory to outgrow its existing factory capacity as early as Q2 2023. Outpacing the capacity of the existing factory space was anticipated and planning for additional production capacity is well underway.

“The groundwork for this capacity increase was laid with investments made at Prodigy in 2021,” said Company COO Jon Rice. “The leadership and team that we have put in place at Prodigy continue to hit their marks, and our investments in equipment and personnel are delivering the rewards we envisioned. I expect that we will have many exciting updates on Prodigy and the commercialization of our eco-friendly and cost effective spider silk in the coming months.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Company is in its strongest financial position ever, having raised $8 million in 16 months

ANN ARBOR, Mich., – April 14, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has received another $1.5 million from YAII PN, Ltd (“YAII”) a fund managed by Yorkville Advisors Global, LP (“Yorkville”). The $1.5 million received this week is the second half of a $3 million fund agreement signed with YAII in January 2022. This $3 million and those from the previously announced transactions account for an $8 million total YAII investment into Kraig Labs over the past 16 months.

The Company is well underway, putting this impact capital to work, strengthening its production operations. Over the last nine months, the Company has deployed capital to build additional production capacity and bring key onsite quality control systems online. These renovations included building out custom-designed rearing rooms, purchasing and installing custom automated production equipment, and planting onsite mulberry to support year-round operations. This work also included the construction of a fully operational molecular biology laboratory that provides onsite and in-process quality control, mirroring the capabilities of the Company’s U.S.-based R&D labs.

“This capital is allowing us to make strategic investments in critical processing, facilities, and equipment that have dramatically enhanced our production capabilities and capacity. Prodigy Textiles is now fully operational and beginning to fulfilling its mission of bringing eco-responsible and cost-effective spider silk to the global textile markets,” said Company COO, Jon Rice.

Maxim Group LLC acted as the sole placement agent for this capital raise.

The Company thanks Maxim Group LLC and Yorkville for their continued trust and confidence in Kraig Labs and its disruptive innovation of the technical textile markets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 7, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announced significant advancements in its Vietnam based production facility, Prodigy Textiles.

The collaboration between the Company’s US and Vietnam lab teams has resulted in their first complete genetic screening of in-process production silkworms. This fifth generation of silkworms, now being reared in Vietnam, is the first production cycle of silkworms at the factory to receive 100% genetic screening. This level of testing, for Kraig Labs, was previously only available at the Company’s R&D headquarters is now being fully transferred to the Vietnamese lab team. 

Earlier this month, the Company flew in an expert trainer to provide hands-on training with new staff members of its expanded R&D team at Prodigy Textiles. In the coming weeks, Kraig Labs’ senior scientist will be at Prodigy Textiles to build on that training and bring additional competencies to the lab in Vietnam. Working together, the Prodigy and Kraig Labs’ teams will screen the sixth generation eggs, the largest expected single production cycle in the Company’s history, and prepare the lab for its expanding role in supporting silk production.

“Transferring this screening technology to Prodigy was the final element needed for our operations team in Vietnam to complete scaling up output to match our facility capacity,” said COO Jon Rice. “With our lab team at Prodigy taking over this crucial testing, I believe our team in Vietnam is now ready to boost monthly silk production targets by 20-50 times current levels.”

In the coming months, the Company also expects to begin harvesting is own supply of fresh mulberry that it began planting in December of last year. This onsite supply will play a critical role is allowing the Company to continue to expand the production of spider silk analog fibers and yarns and to deliver materials to its current and anticipated future end market channel partners.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 16, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the United State Patent and Trademark Office (USPTO) has recently published two key patent applications filed by the Company. These two USPTO patent applications build on Kraig Labs’ innovative recombinant spider silk technologies.

These USPTO patent applications are based upon three provisional patents filed in July of 2020. The two consolidated applications were filed in July of 2021. This is the first opportunity for the public to take a look under the hood to see what this powerful intellectual property encompasses and the opportunities they may unlock.

The first of these USPTO applications, titled “Synthesis of High Molecular Weight Proteins Using Inteins”, reinvents the Company’s approach to manufacturing large-format spider silk protein. This new technology allows for the automated self-assembly of target proteins within the silkworm. This process allows for the opportunity to reach beyond the limits of current protein synthesis technologies. 

This new approach, using the auto-processing capabilities of Inteins, creates the opportunity to create plug-and-play blends of numerous spider silk proteins that are not inhibited by the current size limitation for targeted gene knock-in knock-out transformations. 

The second of these USPTO applications, titled “Synthesis of Non-Native Proteins in Bombyx Mori by Modifying Sericin Expression”, moves beyond the heavy chain fibroin and creates opportunities for co-production of non-fibrous proteins within sericin. Sericin is the stick glue-like protein holding the silk fibers together, making up roughly 20% of the cocoon, and is broadly considered a waste product. 

This invention seeks to leverage this untapped resource to increase the production of target proteins. These target materials include a range of possible applications, including therapeutic and pharmacological proteins. The current production systems for these proteins are inefficient and, therefore, very expensive. This new process opens the possibility for large-scale production materials such as elastin, keratin, human collagen, and many more at comparatively very low costs.

“Our research team continues to deliver, developing novel and innovative applications for our gene-editing technologies,” said COO Jon Rice. “While our production operations in Vietnam remain laser-focused on the large-scale commercial production of spider silk textiles, our lab is busy executing on the technology roadmap to secure Kraig Labs’ future and legacy.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – February 10, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the delivery of Dragon Silk yarn to Spydasilk Enterprises (“Spydasilk”). Spydasilk is a Singapore-based joint venture between Kings Golden Harvest (“Kings”) and Kraig Labs focused on the commercial sale of luxury streetwear and apparel derived from spider silk.

Spydasilk will process the Company’s recombinant spider silk yarn, trade named Dragon Silk, into premium fabrics and garments. Spydasilk expects to make these products available through a combination of direct sales and traditional retail channels.

“Our partnership with Kings and the Spydasilk brand gives us a very exciting direct-to-consumer sales channel,” said Jon Rice, COO of Kraig Labs. “This first small shipment of Dragon Silk will be used to develop the first fabrics in the Spydasilk family of products. Our unique and proprietary spider silk technology paired with Kings branding and marketing expertise should elevate the Spydasilk brand and create sales opportunities for the Company.”

“We are thrilled with the arrival of the Dragon Silk samples in Singapore. This will unfold the progressive plan to work with many big brands with this material that is both associated with modern science as well as sustainable. The counterparties involved are excited to push out the concepts that were in the pipeline since the beginning of the discussions,” said Spydasilk and Kings Group marketing director, Dai Jiajun.

In the coming weeks, the Company expects to be ready to formally launch the Spydasilk website and brand.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Readies for First Commercial Shipment of Recombinant Spider Silk and Accelerated Growth in Production

Kraig Biocraft Laboratories’ Research Team Readies Next Breakthrough in Recombinant Spider Silk Performance

Rapid Expansion of recombinant Spider Silk production on track to grow Operations and yield Fibers for first significant fabric production run

Kraig Biocraft Laboratories Announces Chairman and CEO Letter to Shareholders